Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Common Equity (2024 - 2025)

Historic Common Equity for Genmab A (GMAB) over the last 2 years, with Q3 2025 value amounting to $10.0 million.

  • Genmab A's Common Equity changed 0.0% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $10.0 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Genmab A's Common Equity is $10.0 million, which was down 0.0% from $10.0 million recorded in Q2 2025.
  • Genmab A's Common Equity's 5-year high stood at $10.0 million during Q1 2024, with a 5-year trough of $10.0 million in Q1 2024.